BioCardia Inc (BCDA) has shared an announcement.
BioCardia, Inc. has announced the results of a significant phase of their CardiAMP® Cell Therapy trial, which focuses on treating chronic myocardial ischemia. The exciting findings were shared in a webcast by leading cardiologists, Dr. Carl Pepine and Dr. Amish Raval. This update, while informative for investors and stakeholders, is not considered formally “filed” information regarding legal and regulatory frameworks, but it provides an optimistic glimpse into the potential advancements BioCardia is making in cardiac therapy.
See more insights into BCDA stock on TipRanks’ Stock Analysis page.
